Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Operating Leases: 2022-2025

Historic Operating Leases for Day One Biopharmaceuticals (DAWN) over the last 3 years, with Sep 2025 value amounting to $2.7 million.

  • Day One Biopharmaceuticals' Operating Leases rose 7.64% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year increase of 7.64%. This contributed to the annual value of $2.6 million for FY2024, which is N/A change from last year.
  • Latest data reveals that Day One Biopharmaceuticals reported Operating Leases of $2.7 million as of Q3 2025, which was down 4.14% from $2.9 million recorded in Q2 2025.
  • Day One Biopharmaceuticals' 5-year Operating Leases high stood at $2.9 million for Q1 2025, and its period low was $77,000 during Q3 2023.
  • Its 3-year average for Operating Leases is $1.8 million, with a median of $2.6 million in 2024.
  • As far as peak fluctuations go, Day One Biopharmaceuticals' Operating Leases crashed by 85.02% in 2023, and later soared by 3,196.10% in 2024.
  • Day One Biopharmaceuticals' Operating Leases (Quarterly) stood at $408,000 in 2022, then slumped by 85.02% to $77,000 in 2023, then soared by 3,196.10% to $2.6 million in 2024, then grew by 7.64% to $2.7 million in 2025.
  • Its last three reported values are $2.7 million in Q3 2025, $2.9 million for Q2 2025, and $2.9 million during Q1 2025.